We specialise in the development and manufacture of cell therapies for the regenerative treatment of articular cartilage defects using only the patient’s own cartilage cells. Our cell therapies are a regenerative method that in many cases can make it possible to avert or postpone the need for joint replacement surgery. Our therapies are classified as prescription-only medicinal products and are increasingly used on a day-to-day basis in hospitals by orthopaedic and accident surgeons.
Our production facility offers modern technology for the cultivation of human cells – for the production of our own products and for contract manufacturing.
Our more than 100 employees come from many very different professional backgrounds - scientists, researchers, manufacturing and quality control specialists, engineers, experts for regulatory affairs, clinical trials, market access, communication and many other areas. Together they work every day to ensure that our company is a reliable partner for the physicians using our products in hospitals. Hand in hand, they guarantee the highest product quality for the benefit of patients and contract manufacturing customers.
As experts for human cells we want to provide a regenerative, personalised treatment for every patient using their own cells, which enables them to enjoy an active life. Our mission and vision statements express this: they sum up what we strive for and the commitments we make in our daily work. Our company values define the core elements of our corporate culture and thus what is important to us in our daily work as well as when cooperating with our colleagues and customers.
Establishment of co.don GmbH in Teltow (focus: contract research)
First company in Germany to receive manufacturing licence for autologous cell transplants under Section 13 German Pharmaceuticals Act (AMG)
First patient treated
Development of independent manufacturing technology – Integrated Isolator Technology (IIT) – and operational launch of proprietary cleanroom production plant
co.don GmbH becomes CO.DON AG
Initial public offering (IPO) on 14 February 2001
Start of clinical trials phase II and phase III
EU authorisation received and start of EU expansion
Construction start second production site at Leipzig
End of clinical trial phase II
co.don schweiz gmbh: regulatory approval in Switzerland
Leipzig site: manufacturing license granted for Leipzig site (national level)
End of clinical trial phase III
Leipzig site: approval for Leipzig site granted by EMA